Results 281 to 290 of about 124,170 (327)

A NOTCH3 pathogenic variant influences osteogenesis and can be targeted by antisense oligonucleotides in induced pluripotent stem cells. [PDF]

PLoS One
Canalis E, Yu J, Schilling L, Jafar-Nejad P, Carrer M.   +4 more
europepmc   +1 more source

Efficacy, biodistribution and safety comparison of chemically modified antisense oligonucleotides in the retina. [PDF]

Nucleic Acids Res
Vázquez-Domínguez I, Anido AA, Duijkers L, Hoppenbrouwers T, Hoogendoorn ADM, Koster C, Collin RWJ, Garanto A.   +7 more
europepmc   +1 more source

Exploring precision therapeutics: computational design of antisense oligonucleotides targeting AXL gene transcripts in multiple sclerosis treatment management. [PDF]

Front Chem
Shreevatsa B, Nagaraj A, Dharmashekar C, Jain A, Harendra B, Siddalingegowda SV, Al-Mazroua HA, Ahmad SF, Prasad SK, Srinivasa C, Shivamallu C, Kollur SP.   +11 more
europepmc   +1 more source

Antisense Oligonucleotides for Rapid Translation of Gene Therapy in Glioblastoma. [PDF]

Cancers (Basel)
Desgraves JF, Mendez Valdez MJ, Chandar J, Gurses ME, Henderson L, Castro JR, Seetheram D, Ivan ME, Komotar RJ, Shah AH.   +9 more
europepmc   +1 more source

Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system. [PDF]

Mol Ther
Moazami MP, Rembetsy-Brown JM, Sarli SL, McEachern HR, Wang F, Ohara M, Wagh A, Kelly K, Krishnamurthy PM, Weiss A, Marosfoi M, King RM, Motwani M, Gray-Edwards H, Fitzgerald KA, Brown RH, Watts JK.   +16 more
europepmc   +1 more source

mRNA-specific readthrough of nonsense codons by antisense oligonucleotides (R-ASOs). [PDF]

Nucleic Acids Res
Susorov D, Echeverria D, Khvorova A, Korostelev AA.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Antisense Oligonucleotides

Nephron Experimental Nephrology, 1998
Antisense technology was developed to inhibit gene expression by utilizing an oligonucleotide complementary to the mRNA which encodes the target gene. There are a few possible mechanisms for the inhibitory effects of antisense oligonucleotides. Among them, degradation of mRNA by RNase H is considered to be the major mechanism of action for antisense ...
N, Kashihara, Y, Maeshima, H, Makino
openaire   +2 more sources

Pharmacokinetics of Antisense Oligonucleotides

Clinical Pharmacokinetics, 1995
Antisense oligonucleotides are promising therapeutic agents for the treatment of life-threatening diseases. Intravenous injection of phosphodiester oligonucleotide analogue (P-oligonucleotide) in monkeys shows that the oligonucleotide is degraded rapidly in the plasma with a half-life of about 5 minutes.
Wayne M. Galbraith, Jin-Yan Tang, Sudhir Agrawal, Jamal Temsamani   +3 more
openaire   +2 more sources

Antisense oligonucleotides in cancer

Current Opinion in Oncology, 2014
Over the past several dozen years, regardless of the substantial effort directed toward developing rational oligonucleotide strategies to silence gene expression, antisense oligonucleotide-based cancer therapy has not been successful. This review focuses on the most likely reasons for this lack of success, and on the barriers that still need to be ...
Daniela Castanotto, Cy A. Stein
openaire   +3 more sources